MannKind Corporation (MNKD)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, MannKind Corporation currently loses $17.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 55 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About MannKind Corporation
MannKind Corporation develops and commercializes respiratory-delivered therapies in biotechnology and trades on the NASDAQ under MNKD. Its work centers on endocrine and pulmonary drug products, led by Afrezza and Thyquidity, and it generated $349.0 million of revenue in FY2025 from marketed therapies and development-stage programs.
Today's Snapshot
MNKD ended yesterday 5.3% down at 3.94. MannKind is pursuing inhaled weight-loss treatments using its drug-delivery technology.
Trading Volume
Above 10d avg 2.9M
5.1M
vs S&P 500 Today
Strong Underperformance
-4.81%
Updated: September 10, 2026 at 12:16 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$3.91 - $4.31Sell
- RSI (14)47.22Neutral
- Stochastic %K (14, 3, 3)32.18Neutral
- MACD Level (12, 26)0.01Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.